Navigation Links
Reportlinker Adds Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin
Date:2/17/2011

NEW YORK, Feb. 17, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin

http://www.reportlinker.com/p0397056/Antifungals-Market-to-2016---Promising-Antifungals-in-Pipeline-Includes-Novel-Azoles-Polyenes-and-Echinocandin.html

Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin

Summary

GBI Research, a leading business intelligence provider, has released its latest research "Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin", which provides insights into antifungals sales and price forecasts until 2016. The report examines global treatment usage patterns of antifungals therapies. The geographical distribution of antifungals therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report includes insights into the antifungals R&D pipeline and potential future blockbusters up to 2016. The report provides an in-depth analysis of the top three antifungals therapeutic indications, which are aspergillosis, dermatophytosis and candidiasis. It also includes the market forecasts and treatment usage patterns of these three therapeutic indications. The report explores the competitive landscape including top companies benchmarking, and the key trend analysis on Mergers and Acquisitions (M&A) and licensing agreements involving antifungals therapies are also presented. In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by GBI Research's team of experts. GBI Research's analysis showed that the global antifungals market was estimated at $7.4 billion in 2009, with a year-on-year growth rate of 2.3% between 2001 and 2009. The antifungals market is dominated by target therapeutics, which is more efficient and safe when compared to other conventional therapies. GBI Research forecasts that the market will grow at a Compound Annual Growth Rate (CAGR) of 1.9% between 2009 and 2016 to record a sales value of $8.4 billion. The patent expiry of the major drugs has also paved the way for the entry of generics.

Scope

The scope of this report includes -

- Annualized market data for the antifungals market from 2001 to 2009, with forecasts to 2016.

- Market analysis for the three major indications in the global antifungals market which includes Aspergillosis, Dermatophytosis and Candidiasis.

- Data and analysis on the antifungals market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- The competitive landscape of the global antifungals market including SWOT analysis

- Key M&A activities and licensing agreements that took place in 2008 and 2009 in the antifungals market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious..

To order this report:

: Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):